Halobetasol propionate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for halobetasol propionate and what is the scope of freedom to operate?
Halobetasol propionate
is the generic ingredient in five branded drugs marketed by Padagis Israel, Mayne Pharma, Cosette, Fougera Pharms, Taro, Sun Pharm Inds Inc, Bausch, Mical Pharms, Encube, and Quagen, and is included in nineteen NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Halobetasol propionate has seventy-five patent family members in twenty-seven countries.
There are nine drug master file entries for halobetasol propionate. Nine suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for halobetasol propionate
International Patents: | 75 |
US Patents: | 13 |
Tradenames: | 5 |
Applicants: | 10 |
NDAs: | 19 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 49 |
Clinical Trials: | 21 |
Patent Applications: | 6,827 |
Drug Prices: | Drug price trends for halobetasol propionate |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for halobetasol propionate |
What excipients (inactive ingredients) are in halobetasol propionate? | halobetasol propionate excipients list |
DailyMed Link: | halobetasol propionate at DailyMed |
Recent Clinical Trials for halobetasol propionate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dermatology Consulting Services, PLLC | Phase 4 |
Icahn School of Medicine at Mount Sinai | Phase 3 |
Citius Pharmaceuticals, Inc. | Phase 2 |
Generic filers with tentative approvals for HALOBETASOL PROPIONATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | UNKNOWN | UNKNOWN |
⤷ Sign Up | ⤷ Sign Up | 0.01%;0.045% | LOTION;TOPICAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for halobetasol propionate
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for HALOBETASOL PROPIONATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LEXETTE | Topical Foam | halobetasol propionate | 0.05% | 210566 | 1 | 2021-01-28 |
BRYHALI | Lotion | halobetasol propionate | 0.01% | 209355 | 1 | 2019-05-15 |
ULTRAVATE | Lotion | halobetasol propionate | 0.05% | 208183 | 1 | 2018-01-24 |
US Patents and Regulatory Information for halobetasol propionate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Quagen | HALOBETASOL PROPIONATE | halobetasol propionate | OINTMENT;TOPICAL | 213560-001 | Oct 6, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Padagis Israel | HALOBETASOL PROPIONATE | halobetasol propionate | LOTION;TOPICAL | 211464-001 | Jun 3, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for halobetasol propionate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sun Pharm Inds Inc | ULTRAVATE | halobetasol propionate | CREAM;TOPICAL | 019967-001 | Dec 27, 1990 | ⤷ Sign Up | ⤷ Sign Up |
Sun Pharm Inds Inc | ULTRAVATE | halobetasol propionate | OINTMENT;TOPICAL | 019968-001 | Dec 17, 1990 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for halobetasol propionate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2568598 | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СОДЕРЖАЩИЕ КОРТИКОСТЕРОИДЫ, ДЛЯ ТОПИКАЛЬНОГО ПРИМЕНЕНИЯ (PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL APPLICATION) | ⤷ Sign Up |
China | 108601726 | 含有皮质类固醇的泡沫组合物及其制备方法 (CORTICOSTEROID CONTAINING FOAM COMPOSITIONS AND METHOD OF MANUFACTURE THEREOF) | ⤷ Sign Up |
China | 104884043 | Topical steroid composition and method | ⤷ Sign Up |
Canada | 2888853 | PROCEDE ET COMPOSITION DE STEROIDE TOPIQUE (TOPICAL STEROID COMPOSITION AND METHOD) | ⤷ Sign Up |
Philippines | 12015500859 | TOPICAL STEROID COMPOSITION AND METHOD | ⤷ Sign Up |
Malaysia | 188053 | CORTICOSTEROID CONTAINING FOAM COMPOSITIONS AND METHOD OF MANUFACTURE THEREOF | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.